Beijing Jan. 23 (xinhua) of the communist party of China central committee general secretary and state President and central military commission, chairman of the central comprehensively deepen reform leading group leader xi jinping on January 23rd, chaired a meeting of the second session of the central comprehensively deepen reform leading group and delivered an important speech. He stressed that in 2018, is to implement the party's 19 of the great spirit, also is the 40th anniversary of reform and opening up, to do a good job of reform is of great significance. To promote the reform and innovation spirit, and promote ideological liberation reform further work to grasp, to gather comprehensive ability to deepen the reform, realize new breakthrough in a new starting point.

Conference pointed out that the reform and perfect the generic drug supply security and use of the policy, should start from the demand, the clinical curative effect is necessary, and in short supply, prevention and control of major infectious diseases and rare diseases, treatment of emergent public health event, children's drugs, etc, as the key to promote generic drugs research and development innovation, improve quality of curative effect, improve the ability of drug supply security, better guarantee the people demand.

CDE carding on drugs that accords with a condition:

1. The clinical need, shortage of drugs (7)

2. 防治重大传染病药物（2 个）

3.防治罕见病药物（6 个）

4.儿童用药药物（15 个）

For urgent clinical needs varieties has not been approved, there will be a corresponding policies to speed up the approval.

CFDA follow-up will continue to optimize this part for urgent clinical needs of drug approval procedures for the review, listed on the acceleration on the basis of a certain condition, to reduce the cost of enterprise development.

For urgent clinical needs listed approved drugs, there will be a corresponding policy to give preferential treatment.

Will pass into the medical insurance directory, tender and bid, the reimbursement ratio and so on, of patients with improve enterprise drug post-marketing returns to the greatest extent.

A series of policies introduced underline the CFDA emphasis for priority review work. CFDA trying to do their own work and speed up the urgent clinical needs by conveying speed of generic drugs to market.

At the same time, also in a policy is good to attract attention, call for more enterprises to join urgent clinical needs by drugs. Ultimate goal is always consistent, let people can really "to use medicine" "with affordable medicine".